Search

Your search keyword '"PRAME"' showing total 957 results

Search Constraints

Start Over You searched for: Descriptor "PRAME" Remove constraint Descriptor: "PRAME"
957 results on '"PRAME"'

Search Results

1. Evaluation of PRAME immunohistochemistry in cutaneous vascular neoplasms reveals frequent expression in primary and post‐irradiation cutaneous angiosarcomas.

2. The Utilization of PRAME in the Diagnosis, Prognosis, and Treatment of Melanoma.

3. Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis.

4. PRAME Immunohistochemistry in Thin Melanomas Compared to Melanocytic Nevi.

5. BRCA1‐associated‐protein‐1 inactivated melanocytic tumours: characterisation of the clinicopathological spectrum and immunohistochemical expression pattern of preferentially expressed antigen in melanoma.

6. Metastatic triple‐negative breast carcinoma mimicking melanoma: A potential diagnostic pitfall.

7. Broadening alloselectivity of T cell receptors by structure guided engineering

8. PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans

10. Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma.

11. Malignant melanoma arising in a burn scar.

12. Shedding light on PRAME expression in dysplastic nevi: a cohort study.

13. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas

15. Update on patterns of use of a genetic expression profiling adhesive test to detect melanoma: a cross-sectional survey of academic pigmented lesion experts and private practice clinicians

16. Targeting PRAME for acute myeloid leukemia therapy.

17. Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes.

18. PRAME promotes proliferation of multiple myeloma cells through CTMP/Akt/p21/CCND3 axis by ubiquitinating CTMP and p21

19. The Utilization of PRAME in the Diagnosis, Prognosis, and Treatment of Melanoma

20. PRAME Immunohistochemistry in Thin Melanomas Compared to Melanocytic Nevi

21. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.

22. PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma.

23. The use of immunohistochemical staining in Mohs micrographic surgery for melanoma: a systematic review.

24. Refining the application of PRAME—a useful marker in high CSD and acral melanoma subtypes.

25. Double Immunohistochemical Labelling of PRAME and Melan A in Slow Mohs Biopsy Margin Assessment of Lentigo Maligna and Lentigo Maligna Melanoma

26. Penile melanoma: a pathological report of two cases

27. Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target

28. Intrinsic disorder in PRAME and its role in uveal melanoma

31. Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation.

32. PRAME‐negativity in sclerosing nevi with pseudomelanomatous features supports classification as an indolent lesion.

33. Penile melanoma: a pathological report of two cases.

34. PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival.

35. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.

36. Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target.

37. RNA analysis of tape strips to rule out melanoma in lesions clinically assessed as cutaneous malignant melanoma: A diagnostic study.

38. Conceptos modernos en tumores melanocíticos

39. HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway

40. PRAME immunohistochemistry compared to traditional FISH testing in spitzoid neoplasms and other difficult to diagnose melanocytic neoplasms

41. Intrinsic disorder in PRAME and its role in uveal melanoma.

42. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.

43. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.

44. Diagnostic test accuracy meta‐analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions.

45. PRAME Staining in Sinonasal Mucosal Melanoma: A Single-Center Experience.

47. Skin

48. PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ.

49. PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma.

50. Quantitative expression evaluation of PRAME gene in osteosarcoma.

Catalog

Books, media, physical & digital resources